Sirolimus Rx

Sirolimus tablets and reconstituted vials have different rules. Here's what USP labeling, FDA data and pharmacist guidance say about heat, cold and light.

Blood levels build in 5-8 days, but longevity benefits (if any) are unproven in humans. Here's the real timeline for mTOR inhibition, side effects, and labs.

Sirolimus Rx comes as a lyophilized powder that needs reconstitution before dosing. Here is the exact process, storage rules, and dosing math, step by step.

A buyer's checklist for verifying sirolimus (rapamycin) quality: pharmacy licensing, USP standards, third-party testing, and what a legit provider actually shows you.

Sirolimus is FDA approved as an immunosuppressant, not for longevity. Here's what's approved, what's off-label, and what the human data actually shows.

Sirolimus is FDA-approved for transplant use at immunosuppressive doses. For longevity, it's off-label with no completed human lifespan trial. Here's the real risk data.

Sirolimus isn't on WADA's Prohibited List by name, but its immunosuppressive and metabolic effects raise real questions. Here's what athletes need to know.

Sirolimus and blood work explained: lipid panel, CBC, glucose, trough levels. What off-label users test, how often, and why the human safety data is thin.

Mice on rapamycin live 9-14% longer (NIA ITP data). Zero completed human lifespan trials exist. Here's the honest gap between the mouse data and the hype.

What a sirolimus certificate of analysis actually verifies, what it can't tell you, and how to read one before you trust a compounded vial.

No completed human lifespan trial exists for sirolimus. Here's what PEARL, mouse ITP data, and transplant safety records actually show, with sources.

Compounded sirolimus needs a prescription and USP <795> oversight; 'research' vials skip both. Here's what actually differs, and why it matters for safety.

Sirolimus (rapamycin) is contraindicated in pregnancy, active infection, and certain lung and liver conditions. No human longevity trial exists to weigh against these risks.

Generic sirolimus runs roughly $25 to $100+ a month at retail; compounded off-label vials often cost $150 to $400+. Here's the real pricing breakdown.

Most off-label rapamycin protocols use once-weekly dosing, not cycles with breaks. Here's what the human PK data and mouse studies actually support.

Sirolimus longevity dosing runs 1-10mg weekly off-label, but no completed human lifespan trial exists. See the mouse data, risks, and dosing logic.

No validated sirolimus dosage calculator exists for longevity use. Here's what human trial and transplant data actually show, and how doses get set in practice.

CYP3A4/P-gp interactions, grapefruit, vaccines, and the immunosuppression risk of off-label rapamycin. What actually matters, backed by FDA labeling and NIH data.

Sirolimus has a mean elimination half-life of about 62 hours in adults. Here's what that means for dosing intervals, blood levels, and clearing the drug.

How sirolimus is actually injected off-label for longevity use, needle size, sites, storage, and the human-trial gap that still exists at every step.

No completed human trial has tested rapamycin for lifespan. Here's every real human study on sirolimus and aging, what it found, and what's still missing.

No human lifespan trial has ever tested rapamycin in women. Here's what mouse data, transplant records, and off-label reports actually say about sex differences.

Sirolimus isn't an injectable in standard use. Here's why, how oral dosing actually works, and what 'injection site' questions usually really mean.

Sirolimus is FDA-approved for transplant rejection, not aging. Longevity dosing is 100% off-label and legal only via prescription. Here's the real regulatory picture.

No human trial has tracked low-dose rapamycin past a few years. Here's what transplant data, mouse studies, and case reports tell us about long-term risk.

Sirolimus blocks mTORC1 to mimic caloric restriction in mice, extending median lifespan 9-14%. No completed human lifespan trial exists. Here's the biology.

Sirolimus needs a prescription in the US, no exceptions. Here's what that means for longevity dosing, telehealth routes, and why FDA has approved zero anti-aging use.

Compounded sirolimus isn't FDA-batch-tested like Rapamune. Here's what USP <795> means, what a COA should show, and what to ask before you buy.

Rapamycin extends mouse lifespan 9-26% per NIA data. Human longevity trials don't exist yet. Here's the real evidence, gaps, and risks explained.

Mouth ulcers, high cholesterol, low white cells: sirolimus's real side effect profile, drawn from transplant data, since no completed human longevity trial exists.

How to store sirolimus (rapamycin) correctly, how long reconstituted vials last, and what heat, light, and freezing actually do to potency. Real numbers, real sources.

What actually happens on a low-dose rapamycin protocol, week 1 through month 6, based on trial data and pharmacokinetics. No completed longevity trial exists.

Both extend mouse lifespan in the NIA ITP. Only one is FDA-approved for anything. Here's how rapamycin and acarbose actually compare for longevity use.

Rapamycin extends mouse lifespan up to 26% in NIA-funded trials; metformin's own aging trial (TAME) never got funded. Neither has human longevity data.

Sirolimus has decade-long mouse lifespan data from the NIA's ITP; NAD+ boosters mostly have biomarker studies. Neither has a completed human lifespan trial.

Sirolimus and rapamycin are the same drug. Everolimus is a cousin. Here's what differs in half-life, dosing, and the human longevity data (none of it complete).

Rapamycin has NIA-backed mouse lifespan data; senolytics like dasatinib+quercetin don't. Neither has a completed human lifespan trial. Compare the evidence.

Sirolimus (rapamycin) blocks mTOR and extends mouse lifespan up to 26%. No completed human longevity trial exists. Here's the real evidence.